Endothelial cell activation in thrombotic thrombocytopenic purpura (TTP): a prospective analysis

被引:7
作者
de Wit, TR
Fijnheer, R
Brinkman, HJ
Kersting, S
Hene, RJ
van Mourik, JA
机构
[1] CLB, Sanguin Res, Dept Plasma Prot, NL-1066 CX Amsterdam, Netherlands
[2] Univ Med Ctr Utrecht, Dept Haematol, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Nephrol, Utrecht, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
关键词
endothelial cells; thrombotic thrombocytopenic purpura; vascular perturbation; von Willebrand factor (VWF); VWF-propeptide;
D O I
10.1046/j.1365-2141.2003.04645.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is generally assumed that endothelial cell injury is the primary event in the pathogenesis of thrombotic thrombocytopenic purpura (TTP). In this study, we have determined the extent of vascular perturbation during acute episodes of the disease. We performed a prospective, serial study of nine patients with relapsing TTP during hospitalization and treatment, and assessed the degree of endothelial cell involvement at admission, exacerbation and remission by measurement of von Willebrand factor (VWF) and VWF-propeptide levels. Measurement of both VWF and its propeptide enabled discrimination between acute and chronic perturbation of the endothelium. Elevated levels of both VWF and propeptide were found at admission. These levels decreased immediately upon plasma exchange therapy. However, plasma VWF and propeptide concentrations did not change, even at the time of acute exacerbation. These observations suggest that endothelial cell activation is not the primary event leading to TTP. Vascular perturbation seems to be a consequence, rather than a cause, of the disease.
引用
收藏
页码:522 / 527
页数:6
相关论文
共 15 条
[1]   Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans [J].
Borchiellini, A ;
Fijnvandraat, K ;
tenCate, JW ;
Pajkrt, D ;
vanDeventer, SJH ;
Pasterkamp, G ;
MeijerHuizinga, F ;
ZwartHuinink, L ;
Voorberg, J ;
vanMourik, JA .
BLOOD, 1996, 88 (08) :2951-2958
[2]  
Byrnes J J, 1980, Adv Intern Med, V26, P131
[3]  
Furian M, 1999, THROMB HAEMOSTASIS, V82, P592
[4]   Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome [J].
Furlan, M ;
Robles, R ;
Galbusera, M ;
Remuzzi, G ;
Kyrle, PA ;
Brenner, B ;
Krause, M ;
Scharrer, I ;
Aumann, V ;
Mittler, U ;
Solenthaler, M ;
Lämmle, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (22) :1578-1584
[5]   How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome [J].
George, JN .
BLOOD, 2000, 96 (04) :1223-1229
[6]  
Gerritsen HE, 1999, THROMB HAEMOSTASIS, V82, P1386
[7]   Thrombotic thrombocytopenic purpura: The systemic clumping "Plague" [J].
Moake, JL .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :75-88
[8]  
Moake JL, 1997, SEMIN HEMATOL, V34, P83
[9]   von Willebrand factor and thrombotic thrombocytopenic purpura [J].
Raife, TJ ;
Montgomery, RR .
CURRENT OPINION IN HEMATOLOGY, 2000, 7 (05) :278-283
[10]  
Ruggenenti P, 1996, EUR J HAEMATOL, V56, P191